IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

Andrea G. Cochran et al.

Serial No.: 09/592,695

Filed: June 13, 2000

For: Struc

Structured Peptide Scaffold for

Displaying Turn Libraries on Phage

MAR 0 5 2001

Group Art Unit: 1627

Examiner: B. Koroma

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Assistant Commissioner of Patents, Washington, D.C. 20231 on

February **28**, 2001

Eileen Ly

CERTIFICATE RE: SEQUENCE LISTING

RESPONSE UNDER 37 CFR § 1.821(f) and (g)

Assistant Commissioner of Patents Washington, D.C. 20231

Sir:

I hereby state that the Sequence Listing submitted herewith is submitted in paper copy and a computer-readable diskette, and that the information recorded in computer readable form is identical to the written sequence listing. I further state that this submission includes no new matter.

Respectfully submitted,

GENENTECH, INC.

Date: February 28, 2001

Steven X. Cui

Reg. No. 44,637

Telephone No. (650) 225-8674

PATENT TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, DC 20231
WASHINGTON, DC 20231

APPLICATION NO./ CONTROL NO.09592695 FILING DATE 6/13/00 FIRST NAMED INVENTOR / A. Conchran PATENT IN REEXAMINATION

ATTORNEY DOCKET NO. P1762R1



EXAMINER BARBA M. KOROMA

ART UNIT PAPER 6

DATE MAILED:

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 C.F.R. § 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 C.F.R. §§ 1.821-1.825 for the reason(s) set forth on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures. Applicant must comply with the requirements of the sequence rules (37 CFR 1.821 - 1.825) before the application can be examined under 35 U.S.C. §§ 131 and 132.

Applicant is required to provide separate sequence ID Nos. for each sequence listing that is four or more amino acids or ten or more nucleotides including those listed in the claims, drawings, specifications and all other parts of the application (please see pages 9, 12, 13, 14, 15, 28, 29, 32, and 35).

APPLICANT IS GIVEN ONE MONTH FROM THE DATE OF THIS LETTER WITHIN WHICH TO COMPLY WITH THE SEQUENCE RULES, 37 C.F.R.. §§ 1.821-1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 C.F.R. § 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 C.F.R. § 1.136. In no case may an applicant extend the period for response beyond the six month statutory period. Direct the response to the undersigned. Applicant is requested to return a copy of the attached Notice to Comply with the response.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to [BARBA M. KOROMA] whose telephone number is (703) [305 1915]. The examiner can normally be reached on [8:00a.m -4:00pm].

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, [JYOTHSNA VENKAT] can be reached at (703) [308 2439]. The fax number for the organization where this application or proceeding is assigned is (703) 308-4242. Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist

whose telephone number is (703) 308-0196.

DR. JYOTHSNA VENKAT PHLD SUPERVISORY PATENT EXAMINER TECHNOLOGY CENTER 1600

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

The nucleotide and/or amin acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821 - 1.825 for the following reason(s):

风	1. This application deady fails to comply with the requirements of 37 CFR 1.821 - 1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
X	2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 CFR 1.821(c).
A	3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821
	4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 CFR 1.822 and/or 1.823, as indicated on the attached marked-up copy of the "Raw Sequence Listing."
-	5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be abmitted as required by 37 CFR 1.825(d).
G.	. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" is required by 37 CFR 1.821(e).
7.	Other:
Applic	ant must provide:
An D	Initial or substitute computer readable form (CRF) copy of the "Sequence Listing"
IXI W	initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the
A s new	statement that the content of the paper and computer readable copies are the same and, where applicable, include no matter, as required by 37 CFR 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d)

For questions regarding compliance with these requirements, please contact:

For Rules Interpretation, call (703) 308-1123 For CRF submission help, call (703) 308-4212 For Patentin software help, call (703) 308-6856

Please return a copy of this notice with your response.